Overview of epithelial ovarian cancer and updates in management strategies

Expert Review of Obstetrics and Gynecology

Volumn 4, Issue 4, 2009, Pages 383-399

  Salani, Ritu ^a   Backes, Floor J ^a   Copeland, Larry J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Cytoreductive surgery; Molecular target; Ovarian; Recurrence; Screening; Treatment

Indexed keywords

ALTRETAMINE; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CETUXIMAB; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MATUZUMAB; MELPHALAN; NAVELBINE; OREGOVOMAB; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEMETREXED; PLATINUM DERIVATIVE; TAMOXIFEN; TEMSIROLIMUS; THIOTEPA; TOPOTECAN; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; CANCER INHIBITION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CYTOREDUCTIVE SURGERY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; EPITHELIUM TUMOR; HUMAN; HYSTERECTOMY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVARY CANCER; REVIEW; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; TREATMENT PLANNING;

EID: 77951725525     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.09.18     Document Type: Review

References (164)

1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2005. Ries LAG, Melbert D, Krapcho M et al. (Eds). National Cancer Institute, MD, USA (2007).
2. Kurman RJ, Visvanathan K, Roden R, W TC, Shih IeM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 198(4), 351-356 (2008). (Pubitemid 351451941)
3. Chan W-Y, Cheung K-K, Schorge JO et al. BCL-2 and p53 protein expression, apoptosis, and p53 mutations in human epithelial ovarian cancers. Am. J. Pathol. 156, 409-417 (2000).
4. Salani R, Kurman RJ, Giuntoli R 2nd et al. Assessment of TP53 mutation using purifed tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int. J. Gynecol. Cancer 18(3), 487-491 (2008). (Pubitemid 351668307)
5. Young RH, Scully RE. Differential diagnosis of ovarian tumors based primarily on their patterns and cell types. Semin. Diagn. Path. 18(3), 161-235 (2001).
6. Casagrande JT, Louie EW, Pike MC et al. "Incessant ovulation" and ovarian cancer. Lancet 2, 170-173 (1979).
7. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 2, 163 (1971).
8. Beral V, Doll R, Hermon C, Peto R, Reeves G; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371 (9609), 303-314 (2008).
9. Titus-Ernstoff L, Perez K, Cramer DW et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br. J. Cancer 84, 714-721 (2001). (Pubitemid 32239010)
10. Tworoger SS, Fairfeld KM, Coditz GA et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am. J. Epidemiol. 166, 894-901 (2007).
11. Olson CM, Green AC, Wh item an DC et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and metaanalysis. Eur. J. Cancer 43, 690-709 (2007). (Pubitemid 46502901)
12. Brinton LA, Gridley G, Person I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am. J. Obstet. Gynecol. 176, 572-579 (1997). (Pubitemid 27147164)
13. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of infertility drugs with in-vitro fertilization. Lancet 354, 1586-1590 (1999). (Pubitemid 29515949)
14. Klip H, Burger CW, Leeuwen Van: the Omega Project Group. Risk of hormone-related cancers after ovarian stimulation for in-vitro fertilization in a cohort of 25,152 women. In: Long-term Health Effects of Subfertility Treatment. Klip H (Ed.). PrintPartners Ipskamp B.V., Enschede, The Netherlands, 55-82 (2002).
15. Ness RB, Cramer DW, Goodman MT et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am. J. Epidemiol. 155, 217-224 (2002). (Pubitemid 34117299)
16. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68(3), 700-710 (2001).
17. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343(8899), 692-695 (1994).
18. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296(2), 185-192 (2006).
19. Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer 64(6), 430-433 (1995). (Pubitemid 26048907)
20. Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin. Oncol. 25(3), 255-264 (1998). (Pubitemid 28272601)
21. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291(22), 2705-2712 (2004).
22. Goff BA, Mandel LS, Drescher CW et al. Development of an ovarian cancer symptom index. Cancer 109(2), 221-227 (2007).
23. Partridge E, Kreimer AR, Greenlee RT et al.; the PLCO Project Team. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113(4), 775-782 (2009).
24. Menon U, Skates SJ, Lewis S et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23(31), 7919-7926 (2005). (Pubitemid 46657391)
25. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol. Oncol. 100(1), 20-26 (2006). (Pubitemid 41815044)
26. Visintin, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14, 1065-1072 (2008). (Pubitemid 351302552)
27. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 112(1), 40-46 (2009).
28. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002). (Pubitemid 34178440)
29. Wang J, Zhang X, Ge X, Guo H, Xiong G, Zhu Y. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol. Oncol. 111(1), 111-119 (2008).
30. Schmeler KM, Lynch HT, Chen LM et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 354(3), 261-269 (2006). (Pubitemid 43113031)
31. Powell CB, Kenley E, Chen LM et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 23(1), 127-132 (2005). (Pubitemid 41702631)
32. Rebbeck TR, Lynch HT, Neuhausen SL et al.; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346(21), 1616-1622 (2002). (Pubitemid 34755669)
33. Bristow RE, Santillan A, Diaz-Montes TP et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 109(8), 1513-1522 (2007). (Pubitemid 46595686)
34. Earle CC, Schrag D, Neville BA et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl Cancer Inst. 98, 172-180 (2006). (Pubitemid 43205479)
35. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol. Oncol. 105, 801-812 (2007). (Pubitemid 46734206)
36. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 16(1), 11-17 (2006). (Pubitemid 44376657)
37. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20(5), 1248-1259 (2002).
38. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J. Clin. Oncol. 25, 2873-2883 (2007).
39. Lin PS, Gershenson DM, Bevers MW et al. The current status of surgical staging of ovarian serous borderline tumors. Cancer 85, 905-911 (1999). (Pubitemid 29077568)
40. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J. Clin. Oncol. 25(20), 2928-2937 (2007). (Pubitemid 47123157)
41. Silva EG, Gershenson DM, Malpica A et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with non-invasive implants is time dependent. Am. J. Surg. Pathol. 30, 1367-1371 (2006). (Pubitemid 44655469)
42. Eichhorn JH, Bell DA, Young RH et al. Ovarian serous borderline tumors with micropapillary and cribiform patters: a study of 40 cases and comparison with 44 cases without these patterns. Am. J. Surg. Pathol. 23, 397-409 (1999).
43. Morice P, Camatte S, Rey A et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann. Oncol. 14, 592-598 (2003). (Pubitemid 41295089)
44. Kurman RJ, Seidman JD, Shih IM. Serous borderline tumours of the ovary. Histopathology 47, 310-315 (2005).
45. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis and proposed classifcation. Am. J. Surg. Pathol. 30, 614-624 (2006).
46. Camatte S, Morice P, Thoury A et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumors: analysis of a continuous series of 101 cases. Eur. J. Cancer 40, 1842-1849 (2004). (Pubitemid 39036758)
47. Young RC, Decker DG, Wharton JT et al Staging laparotomy in early ovarian cancer. JAMA 250(22), 3072-3076 (1983).
48. Buchsbaum HJ, Brady MF, Delgado G et al. Surgical staging of carcinoma of the ovaries. Surg. Gynecol. Obstet. 169(3), 226-232 (1989). (Pubitemid 19255049)
49. Liou WS, Yap OW, Chan JK, Westphal LM. Innovations in fertility preservation for patients with gynecologic cancers. Fertil. Steril. 84(6), 1561-1573 (2005). (Pubitemid 41785643)
50. Monk BJ, Disaia PJ. What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate. Int. J. Gynecol. Cancer 15(3), 199-205 (2005).
51. Dexeus S, Labastida R, Dexeus D. Conservative management of epithelial ovarian cancer. Eur. J. Gynaecol. Oncol 26(5), 473-478 (2005). (Pubitemid 41585926)
52. Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: a message of hope for young women. Gynecol. Oncol. 103(3), 1109-1121 (2006). (Pubitemid 44821345)
53. Griffths CT, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat. Rep. 63, 235 (1979).
54. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170(4), 974-979 (1994).
55. Chi DS, Eisenhauer EL, Lang J et al What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 103(2), 559-564 (2006). (Pubitemid 44602167)
56. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol. Oncol. 108, 276-281 (2008).
57. Panici PB, Maggioni A, Hacker N et al Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J. Natl Cancer Inst. 97, 560-566 (2005). (Pubitemid 40723783)
58. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am. J. Obstet. Gynecol. 197(6), 676.e1-676.e7 (2007).
59. Leitao MM, Chi DS. Operative management of primary epithelial ovarian cancer. Curr. Oncol. Rep. 9(6), 478-484 (2007). (Pubitemid 350081484)
60. Aletti GD, Dowdy SC, Gostout BS et al. Aggressive surgical effort and improved survival in advanced stage ovarian cancer. Obstet. Gynecol. 107, 77-85 (2006). (Pubitemid 43755507)
61. Salani R, Zahurak ML, Santillan A, Giuntoli RL II, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol. Oncol. 107, 495-499 (2007). (Pubitemid 350160861)
62. Eisenkop SM, Spirtos NM Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is There A Correlation with "biological Aggressiveness" and Survival? Gynecol. Oncol. 82, 435-441 (2001).
63. Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect ofbowel resection on survival in advanced epithelial ovarian cancer. Gynecol. Oncol. 83, 286-291 (2001). (Pubitemid 33033068)
64. Hoffman MS, Griffn D, Tebes S et al. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am. J. Obstet. Gynecol. 193, 582-586 (2005). (Pubitemid 41159559)
65. Estes JM, Leath CA, Straughn JM et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J. Am. Coll. Surg. 203(4), 527-532 (2006).
66. Tebes SJ, Cardosi R, Hoffman MS. Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am. J. Obstet. Gynecol. 195(2), 585-589 (2006). (Pubitemid 44142393)
67. Cliby W, Dowdy S, Feitoza SS, Gostout BS, Podratz KC. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol. Oncol. 94, 655-660 (2004). (Pubitemid 39194457)
68. Eisenhauer EL, Abu-Rustum NR, Sonoda Y. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103, 1083-1090 (2006). (Pubitemid 44821338)
69. Dowdy SC, Lowewen RT, Aletti G, Feitoza SS, Cliby W. Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol. Oncol. 109(2), 303-307 (2008).
70. van Dam PA, Tialma W, Wevler J, van Oosterom AT, Buytaert P. Ultraradical debulking of epithelial ovarian cancer with ultrasonic surgical aspirator: a prospective randomized trial. Am. J. Obstet. Gynecol. 174(3), 943-950 (1996). (Pubitemid 26111676)
71. Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol. Oncol. 83, 39-48 (2001).
72. Akahira JL, Yoshikawa H, Shimzu Y et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol. Oncol. 81, 398-403 (2001). (Pubitemid 32494653)
73. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72(3), 278-287 (1999). (Pubitemid 29118182)
74. Winter WE, Maxwell L, Tian C et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 28(1), 83-89 (2008).
75. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol. Oncol. 105(1), 84-89 (2007).
76. Juretzka MM, Abu-Rustum NR, Sonoda Y et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol. Oncol. 104(3), 670-674 (2007). (Pubitemid 46240259)
77. Wagensteen OH, Lewis FJ, Tongen LA. The "second-look" in cancer surgery; a patient with colic cancer and involved lymph nodes negative on the "sixth-look". Lancet 71(8), 303-307 (1951).
78. Barnhill DR, Hoskins WJ, Heller PB, Park RC. The second-look surgical reassessment for epithelial ovarian carcinoma. Gynecol. Oncol. 19, 148-154 (1984). (Pubitemid 14024339)
79. Friedman RL, Eisenkop SM, Wang HJ. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol. Oncol. 67(1), 88-94 (1997).
80. Schlaerth AC, Abu-Rustum NR. Role of minimally invasive surgery in gynecologic cancers. Oncologist 11, 895-901 (2006). (Pubitemid 44373762)
81. Greer BE, Bundy BN, Ozols RF et al Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a gynecologic oncology group study Gynecol. Oncol. 99(1), 71-79 (2005).
82. Van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction of chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Engl. J. Med. 332, 629-634 (1995).
83. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351, 2489-2497 (2004). (Pubitemid 39603156)
84. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol. Oncol. 104, 480-490 (2007). (Pubitemid 46135675)
85. Salani R, Santillan A, Zahurak ML et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Cancer 109, 685-691 (2007). (Pubitemid 46135662)
86. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patient selection. Br. J. Cancer 92, 1026-1032 (2005). (Pubitemid 40546664)
87. Zang RY, Li ZT, Tang J et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefts? Cancer 100, 1152-1161 (2004). (Pubitemid 38325942)
88. Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106, 1933-1939 (2006). (Pubitemid 43673208)
89. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 112(1), 265-274 (2009).
90. Harter P, du Bois A, Hahmann et al Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann. Surg. Oncol. 13, 1702-1710 (2006). (Pubitemid 44951480)
91. Pothuri B, Montemarano M, Gerardi M et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol. Oncol. 96, 330-334 (2005). (Pubitemid 40127130)
92. Ganatra A, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J. Urol. 174(6), 2125-2128 (2005). (Pubitemid 41611751)
93. Trope C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J. Clin. Oncol. 25, 2909-2920 (2007). (Pubitemid 47123155)
94. Trimbos JB, Vergote I, Bolis G et al Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: european organization for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J. Natl Cancer Inst. 95, 113-125 (2003). (Pubitemid 36193260)
95. Bell J, Brady MF, Young RC et al (Pubitemid 44353663)
96. Chan JK, Fleming G, Zhang M et al. The potential beneft of six versus three cycles of chemotherapy in subsets of women with high-risk early-stage epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol. Oncol. 113(4), S2-S3 (2008) (Abstract).
97. McGuire III WP, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer 89(3), S3-S8 (2003). (Pubitemid 38067997)
98. Harries M, Gore M Part I: chemotherapy for epithelial ovarian cancer-treatment at frst diagnosis. Lancet Oncol. 3, 529-536 (2002). (Pubitemid 34993640)
99. Lambert HE, Berry RJ. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. BMJ 290(6472), 889-893 (1985).
100. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6 (1996). (Pubitemid 26012496)
101. Ozols RF, Bundy BN, Greer BE et al Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 21, 3194-3200 (2003).
102. Armstrong DK, Bundy B, Wenzel L et al Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006). (Pubitemid 43048949)
103. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529 (2004).
104. Markman M, Bundy BN, Alberts DS et al Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwest oncology group, and eastern cooperative Oncology Group. J. Clin. Oncol. 21, 1313-1319 (2001). (Pubitemid 32176274)
105. Alberts DS, Liu PY, Hannigan EV et al Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950-1955 (1996). (Pubitemid 26428219)
106. Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J. Clin. Oncol. 25, 2867-2872 (2007). (Pubitemid 47123150)
107. Markman M, Liu PY, Wilczynski S et al.; Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21(13), 2460-2465 (2003). (Pubitemid 46606325)
108. Conte PF, Favalli G, Gadducci A et al Final results of After-6 protocol 1: a Phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (abstract). J. Clin. Oncol. 25, S275 (2007).
109. Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn J. Clin. Oncol. 38(6), 445-450 (2008).
110. Bolis G, Danese S, Tateo S et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a Phase II study. Int. J. Gynecol. Cancer 16(1), 74-78 (2006).
111. Pfsterer J, Weber B, Reuss A et al. Randomized Phase III trial of topotecan following carboplatin and paclitaxel in frst-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl Cancer Inst. 98(15), 1036-1045 (2006). (Pubitemid 44288151)
112. De Placido S, Scambia G, Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol 22(13), 2635-2642 (2004). (Pubitemid 41103751)
113. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. 27(3), 418-425 (2009).
114. Verheijen RH, Massuger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defned complete remission. J. Clin. Oncol. 24(4), 571-578 (2006).
115. Muntz HG, Malpass TW, McGonigle KF, Robertson MD, Weiden PL. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma. Cancer 113(3), 490-496 (2008).
116. Diaz-Montes TP, Bristow RE. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr. Oncol. Rep. 7, 451-458 (2005). (Pubitemid 41684231)
117. Harries M, Gore M (Pubitemid 34993641)
118. Herzog TJ. The current treatment of recurrent ovarian cancer. Curr. Oncol. Rep. 8, 448-454 (2006). (Pubitemid 44697774)
119. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(5), 20-28 (2002).
120. Herzog TJ Recurrent ovarian cancer: how important is it to treat to disease progression? Clin. Cancer Res. 10, 7439-7449 (2004).
121. Rose G, Mossbruger K, Fusco N et al. Gemcitabine reverse cisplatin resistance: demonstration of activity in platinum and multidrug resistant ovarian and peritoneal carcinoma. Gynecol. Oncol. 88(1), 17-21 (2003). (Pubitemid 36062660)
122. Bozas G, Bamias A, Koutsouku V et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel pretreated, ovarian and peritoneal carcinoma. Gynecol. Oncol. 104(3), 580-585 (2007). (Pubitemid 46251411)
123. Vergote I, Calvert H, Kania M et al. A randomised, double-blind, Phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur. J. Cancer 45(8), 1415-1423 (2009)
124. du Bois A, Pfsterer J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective Phase II study of Arbeitsgemeinschaft Gynaekologicshe Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol. Oncol. 107(3), 518-525 (2007).
125. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95(1), 1-8 (2004). (Pubitemid 39286270)
126. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16(10), 3345-3352 (1994). (Pubitemid 28481631)
127. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 108, 271-275 (2008).
128. Axtell AE, Lee MH, Bristow RE et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25(4), 384-389 (2007).
129. Nelson BE, Rosenfeld AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol. 11, 166-172 (1993).
130. Vergote I, DeWever I, Tjalma W, van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71, 431-436 (1998). (Pubitemid 29022333)
131. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol. 103, 1070-1076 (2006). (Pubitemid 44821335)
132. Vergote IB, Tropé CG, Amant F et al. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). Presented at: 12th Biennial International Gynecologic Cancer Society Meeting. Bangkok, Thailand, 25-28 October 2008.
133. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S; TCA Ovarian Cancer Trial Group. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physiciani's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18(9), 1093-1101 (2007). (Pubitemid 47294903)
134. Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided therapy. Am. J. Obstet. Gynecol. 189, 1301-1307 (2003). (Pubitemid 37542162)
135. Holloway RW, Mehta RS, Finkler NJ et al. Association between in vitro platinum resistance in the EDR assay and clinical outcome for ovarian cancer patients. Gynecol. Oncol. 87, 8-16 (2002).
136. Gallion H, Christopherson WA, Coleman RL et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int. J. Gynecol. Cancer 16 (1), 194-201 (2006).
137. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005). (Pubitemid 46202320)
138. Wright JD, Secord AA, Numnum TM et al. A multi-institutional evaluation of factors predictive of toxicity and effcacy of bevacizumab for recurrent ovarian cancer. Int. J. Gynecol. Cancer 18(3), 400-406 (2008).
139. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102(2), 140-144 (2006). (Pubitemid 44056265)
140. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(33), 5165-5171 (2007). (Pubitemid 350237599)
141. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25(33), 5180-5186 (2007). (Pubitemid 350232248)
142. Wright JD, Hagemann A, Rader JS et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107(1), 83-89 (2006). (Pubitemid 43939034)
143. Richardson DL, Backes FJ, Seamon LG et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol. Oncol. 111, 461-466 (2008).
144. Han ES, Monk BJ (Pubitemid 46441477)
145. Merritt WM, Lin YG, Han LY et al. Dicer, drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641-2650 (2008).
146. Mabuchi S, Altomare DA, Connolly DC et al RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 67(6), 2408-2413 (2007). (Pubitemid 46548923)
147. Jiang H, Feng Y Hypoxia-inducible factor 1a (HIF-1 a) correlated with tumor growth and apoptosis in ovarian cancer. Int. J. Gynecol. Cancer 16(1), 405-412 (2006).
148. Campone M, Levy V, Bourbouloux E et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br. J. Cancer 100(2), 315-321 (2009).
149. Verheijen RH, Massuger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defned complete remission. J. Clin. Oncol. 24(4), 571-578 (2006).
150. Oei AL, Moreno M, Verheijen RH et al. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int. J. Cancer 123(8), 1848-1853 (2008).
151. Konner J, Schilder RJ, DeRosa FA et al. A Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol. Oncol. 110(2), 140-145 (2008).
152. Secord AA, Blessing JA, Armstrong DK et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol. Oncol. 108(3), 493-499 (2008).
153. Seiden M, Burris HA, Matulonis U et al. A Phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily pretreated and platinum-resistant advanced Mullerian malignancies. Gynecol. Oncol. 104(3), 727-731 (2007). (Pubitemid 46251417)
154. Schilder RJ, Sill MW, Chen X et al. Phase II study of geftinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11, 5539-5548 (2005). (Pubitemid 41060831)
155. Posadas EM, Liel MS, Kwitkowski V et al. A Phase II and pharmacodynamic study of geftinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109(7), 1323-1330 (2007). (Pubitemid 46466559)
156. Nimeiri HS, Oza AM, Morgan RJ et al. Effcacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol. 110(1), 49-55 (2008).
157. Gordon AN, Finkler N, Edwards RP et al. Effcacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer 15(5), 785-792 (2005). (Pubitemid 41783082)
158. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26(22), 3709-3714 (2008).
159. Burges A, Wimberger P, Kümper C et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a Phase I/II study. Clin. Cancer Res. 13(13), 3899-3905 (2007). (Pubitemid 47037597)
160. Juretzka M, Hensley ML, Tew W, Konner J, Aghajanian C, Leitao M. A Phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur. J. Gynaecol. Oncol. 29(6), 568-572 (2008).
161. Downs LS Jr, Judson PL, Argenta PA et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 112(2), 331-339 (2008).
162. Landen CN Jr, Chavez-Reyes A, Bucana C et al Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65(15), 6910-6918 (2005). (Pubitemid 41060730)
163. Wu H, Cao Y, Weng D et al Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett. 271(2), 260-271 (2008).
164. McKeage MJ, Von Pawel J, Reck M et al. Randomised Phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br. J. Cancer 99(12), 2006-2012 (2008).